Repository logo

Seroprevalence of anti-SARS-CoV-2 IgG at the first epidemic peak in French Guiana, July 2020.

Published version



Change log


Alves Sarmento, Christelle 
Enfissi, Antoine 
Bailly, Sarah 


BACKGROUND: While Latin America has been heavily affected by the pandemic, only a few seroprevalence studies have been conducted there during the first epidemic wave in the first half of 2020. METHODOLOGY/PRINCIPAL FINDINGS: A cross-sectional survey was performed between 15 July 2020 and 23 July 2020 among individuals who visited 4 medical laboratories or 5 health centers for routine screening or clinical management, with the exception of symptomatic suggestive cases of covid-19. Samples were screened for the presence of anti-SARS-CoV-2 IgG directed against domain S1 of the SARS-CoV-2 spike protein using the anti-SARS-CoV-2 enzyme-linked immunosorbent assay (ELISA) from Euroimmun. CONCLUSIONS/SIGNIFICANCE: The overall seroprevalence was 15.4% [9.3%-24.4%] among 480 participants, ranging from 4.0% to 25.5% across the different municipalities. The seroprevalence did not differ according to gender (p = 0.19) or age (p = 0.51). Among SARS-CoV-2 positive individuals, we found that 24.6% [11.5%-45.2%] reported symptoms consistent with COVID-19. Our findings revealed high levels of infection across the territory but a low number of resulting deaths, which can be explained by French Guiana's young population structure.


Funder: National Research Agency

Funder: Regional Health Agency of French Guiana

Funder: Institut Pasteur Urgence COVID-19 fundraising


Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Viral, COVID-19, Child, Child, Preschool, Cross-Sectional Studies, French Guiana, Humans, Immunoglobulin G, Infant, Middle Aged, SARS-CoV-2, Seroepidemiologic Studies, Young Adult

Journal Title

PLoS Negl Trop Dis

Conference Name

Journal ISSN


Volume Title



Public Library of Science (PLoS)
European Regional Development Fund (GY0027257)